In addition, PFDN6 serves as a potential biomarker of the prognosis of childhood acute lymphoblastic leukemia (ALL) and might predict the efficacy of chemotherapy (Dehghan-Nayeri et al., 2017). Here, PFDN6 is linked to acute lymphoblastic leukemia.